Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition.

TitleSerum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition.
Publication TypeJournal Article
Year of Publication2007
AuthorsCust, AE, Allen, NE, Rinaldi, S, Dossus, L, Friedenreich, C, Olsen, A, Tjønneland, A, Overvad, K, Clavel-Chapelon, F, Boutron-Ruault, M-C, Linseisen, J, Chang-Claude, J, Boeing, H, Schulz, M, Benetou, V, Trichopoulou, A, Trichopoulos, D, Palli, D, Berrino, F, Tumino, R, Mattiello, A, Vineis, P, J Quirós, R, Agudo, A, Sánchez, M-J, Larrañaga, N, Navarro, C, Ardanaz, E, H Bueno-de-Mesquita, B, Peeters, PHM, van Gils, CH, Bingham, S, Khaw, K-T, Key, T, Slimani, N, Riboli, E, Kaaks, R
JournalInt J Cancer
Volume120
Issue12
Pagination2656-64
Date Published2007 Jun 15
ISSN0020-7136
KeywordsAged, Body Mass Index, C-Peptide, Case-Control Studies, Endometrial Neoplasms, Europe, Female, Humans, Incidence, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor Binding Protein 2, Logistic Models, Middle Aged, Prospective Studies, Risk Factors, Surveys and Questionnaires
Abstract

We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition, to examine the associations between prediagnostic serum concentrations of C-peptide, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-2, and endometrial cancer risk. Among pre- and post-menopausal women, who were not currently using exogenous hormones, 286 women developed incident endometrial cancer during an average 5.1 years follow-up. Using risk set sampling, 555 matched control subjects were selected. In conditional logistic regression models adjusted for matching factors only, endometrial cancer risk increased with increasing serum levels of C-peptide (relative risks (RR) for the top vs. bottom quartile = 2.13 [95% confidence interval (CI) 1.33-3.41], p(trend) = 0.001, and decreasing serum levels of IGFBP-2 (RR for the top vs. bottom quartile = 0.56 [95% CI 0.35-0.90], p(trend) = 0.03, but was not significantly associated with IGFBP-1 levels (RR for the top vs. bottom quartile = 0.76 [95% CI 0.47-1.21], p(trend) = 0.25). In BMI-adjusted models, only the C-peptide association remained marginally statistically significant (RR for the top vs. bottom quartile = 1.56 [95% CI 0.94-2.57], p(trend) = 0.05 for C-peptide; 0.84 [95% CI 0.50-1.40], p(trend) = 0.74 for IGFBP-2; and 1.08 [95% CI 0.65-1.78], p(trend) = 0.86 for IGFBP-1 levels). These associations were stronger among nonfasting women (< or =< or =6 hr since last meal; 63% of subjects) but were not evident among fasting women, although the interactions were not statistically significant. The C-peptide-risk association was substantially attenuated after adjustment for free estradiol in postmenopausal women (RR for the top vs. bottom quartile = 1.28 [95% CI 0.67-2.45], p(trend) = 0.42. Our results provide modest support to the hypothesis that hyperinsulinaemia is a risk factor for endometrial cancer.

DOI10.1002/ijc.22578
Alternate JournalInt. J. Cancer
Citation Key10.1002/ijc.22578
PubMed ID17285578
Grant ListG0401527 / / Medical Research Council / United Kingdom